de Medeiros VA, Ferreira CR,
Silva-Cunha JL, da Silveira EJD, Gordón-Núñez MA, Alves PM, Nonaka CFW.
Immunoexpression of CXCL12 and CXCR4 in giant cell granulomas of the jaws and
giant cell tumor of bone. Med Oral Patol Oral Cir Bucal. 2026 Sep 1;31 (5):e772-81.
doi:10.4317/medoral.28299
https://dx.doi.org/doi:10.4317/medoral.28299
___
References
|
1.
Jordan RC, Gomes CC, Gomez RS. Giant cell lesions and bone cysts. In: Odell
EW, Muller S, Tilakaratne WM, editors. WHO Classification of Tumours: Head
and Neck Tumours. 5th ed. Lyon: International Agency for Research on Cancer;
2024. |
|
|
|
|
|
2.
Flanagan AM, Larousserie F, O'Donnell PG, Yoshida A. Giant cell tumor of
bone. In: Bovée JVMG, Flanagan AM, Lazar AJ, Nielsen GP, Yoshida A, editors.
WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th ed. Lyon:
International Agency for Research on Cancer; 2020. |
|
|
|
|
|
3.
Nagar SR, Bansal S, Jashnani K, Sinha A, Desai RS. A comparative analysis of
p63 expression in giant cell tumour (GCT), central giant cell granuloma
(CGCG) and peripheral giant cell granuloma (PGCG). Head Neck Pathol. 2020;14(3):733-41. |
|
|
|
|
|
4.
Chi Y, Qin Z, Bai J, Yan J, Xu Z, Yang S, Li B. Update on the nature of central
giant cell granuloma of the jaw with a focus on the aggressive subtype.
Pathology. 2025;57(4):461-9. |
|
|
|
|
|
5.
Vered M, Wright JM. Update from the 5th edition of the World Health
Organization Classification of Head and Neck Tumours: Odontogenic and
maxillofacial bone tumours. Head Neck Pathol. 2022;16(1):63-75. |
|
|
|
|
|
6.
Yao Y, Lee VKM, Chen ES. Molecular pathological insights into tumorigenesis
and progression of giant cell tumor of bone. J Bone Oncol. 2025;51:100665. |
|
|
|
|
|
7.
Barros EF, de Medeiros VA, da Silveira ÉJD, Goulart Filho JAV, Alves PM,
Nonaka CFW. Immunohistochemical analysis of immune checkpoint proteins (PD-1,
PD-L1 and PD-L2) in giant cell granulomas of the jaws and giant cell tumor of
bone. Arch Oral Biol. 2026;182:106460. |
|
|
|
|
|
8.
da Fonseca Orcina B, Schemmfelnnig EA, Chamon RCC, Guimarães DM, da Silva
Kataoka MS, de Melo Alves Júnior S, Tarquinio SBC, Vasconcelos ACU, Gomes
APN, Pinheiro JJV, Etges A. An investigation of the differences in cortactin,
MT1-MMP, TKS4, and TKS5 immunoexpression between central and peripheral giant
cell granulomas. J Oral Pathol Med. 2025;54(9):884-94. |
|
|
|
|
|
9.
Barros CCDS, Santos LMDR, Severo MLB, Miguel MCDC, Squarize CH, da Silveira
ÉJD. Morphological analysis of cell cannibalism: An auxiliary tool in the
prediction of central giant cell granuloma clinical behavior. Acta Histochem.
2023;125(7):152091. |
|
|
|
|
|
10.
Sarode GS, Sarode SC, Gawande S, Patil S, Anand R, Patil SG, Patil P.
Cellular cannibalism in giant cells of central giant cell granuloma of jaw
bones and giant cell tumors of long bones. J Investig Clin Dent.
2017;8(2):e12214. |
|
|
|
|
|
11.
Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: Molecular and
functional properties, role in disease and efforts towards pharmacological
intervention. Cell Mol Immunol. 2023;20(3):217-51. |
|
|
|
|
|
12.
Yu J, Zhou X, Shen L. CXCR4-targeted radiopharmaceuticals for the imaging and
therapy of malignant tumors. Molecules. 2023;28(12):4707. |
|
|
|
|
|
13.
Khare T, Bissonnette M, Khare S. CXCL12-CXCR4/CXCR7 axis in colorectal
cancer: Therapeutic target in preclinical and clinical studies. Int J Mol
Sci. 2021;22(14):7371. |
|
|
|
|
|
14.
Nugraha AP, Kitaura H, Ohori F, Pramusita A, Ogawa S, Noguchi T, Marahleh A,
Nara Y, Kinjo R, Mizoguchi I. C-X-C receptor 7 agonist acts as a C-X-C motif
chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone
resorption. Mol Med Rep. 2022;25(3):78. |
|
|
|
|
|
15.
Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P. Stromal
cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor
cells promotes the chemotactic recruitment, development and survival of human
osteoclasts. Bone. 2005;36(5):840-53. |
|
|
|
|
|
16.
De Vita A, Vanni S, Miserocchi G, Fausti V, Pieri F, Spadazzi C, Cocchi C,
Liverani C, Calabrese C, Casadei R, Recine F, Gurrieri L, Bongiovanni A,
Ibrahim T, Mercatali L. A rationale for the activity of bone target therapy
and tyrosine kinase inhibitor combination in giant cell tumor of bone and
desmoplastic fibroma: Translational evidences. Biomedicines. 2022;10(2):372. |
|
|
|
|
|
17.
Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV,
Kim W, Winchester RJ, Young-In Lee F. Recruitment of osteoclast precursors by
stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop
Res. 2005;23(1):203-9. |
|
|
|
|
|
18.
Chuong R, Kaban LB, Kozakewich H, Perez-Atayde A. Central giant cell lesions
of the jaws: A clinicopathologic study. J Oral Maxillofac Surg.
1986;44(9):708-13. |
|
|
|
|
|
19.
Martini G, Capella D, Rivero ERC, Gondak RO. Immunohistochemical expression
of RANKL in oral giant cell lesions is predictive of aggressiveness. Braz
Oral Res. 2018;32:e115. |
|
|
|
|
|
20.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.
Hillsdale (NJ): Lawrence Erlbaum Associates; 1988. |
|
|
|
|
|
21.
Shima K, Kimura K, Ishida M, Kishikawa A, Ogawa S, Qi J, Shen WR, Ohori F,
Noguchi T, Marahleh A, Kitaura H. C-X-C motif chemokine 12 enhances
lipopolysaccharide-induced osteoclastogenesis and bone resorption in vivo.
Calcif Tissue Int. 2018;103(4):431-42. |
|
|
|
|
|
22.
Nengroo MA, Maheshwari S, Singh A, Verma A, Arya RK, Chaturvedi P, Saini KK,
Singh AK, Sinha A, Meena S, Gupta A, Mishra A, Sarkar J, Datta D. CXCR4
intracellular protein promotes drug resistance and tumorigenic potential by
inversely regulating the expression of death receptor 5. Cell Death Dis.
2021;12(5):464. |
|
|
|
|
|
23.
Perpiñá-Viciano C, Işbilir A, Zarca A, Caspar B, Kilpatrick LE, Hill SJ, Smit
MJ, Lohse MJ, Hoffmann C. Kinetic analysis of the early signaling steps of
the human chemokine receptor CXCR4. Mol Pharmacol. 2020;98(2):72-87. |
|
|
|
|
|
24.
Nengroo MA, Khan MA, Verma A, Datta D. Demystifying the CXCR4 conundrum in
cancer biology: Beyond the surface signaling paradigm. Biochim Biophys Acta
Rev Cancer. 2022;1877(5):188790. |
|
|
|
|
|
25.
Bao Y, Wang Z, Liu B, Lu X, Xiong Y, Shi J, Li P, Chen J, Zhang Z, Chen M,
Wang L, Wu Z. A feed-forward loop between nuclear translocation of CXCR4 and
HIF-1α promotes renal cell carcinoma metastasis. Oncogene. 2019;38(6):881-95. |
|
|
|
|
|
26.
Xu Z, Li P, Wei D, Wang Z, Bao Y, Sun J, Qu L, Wang L. NMMHC-IIA-dependent
nuclear location of CXCR4 promotes migration and invasion in renal cell
carcinoma. Oncol Rep. 2016;36(5):2681-8. |
|
|
|
|
|
27.
Stagner AM, Sajed DP, Nielsen GP, Ebb DH, Faquin WC, Chebib I, Rivera MN,
Ting DT, Resnick CM, Peacock ZS, Kaban LB, Deshpande V. Giant cell lesions of
the maxillofacial skeleton express RANKL by RNA in situ hybridization
regardless of histologic pattern. Am J Surg Pathol. 2019;43(6):819-26. |
|
|
|
|
|
28.
Jiang ZY, Jiang JJ, Ma YS, Li HY, Shi W, Fu PL, Xu CF, Lu JZ, Fu D, Xu JG.
Downregulation of miR-223 and miR-19a induces differentiation and promotes
recruitment of osteoclast cells in giant-cell tumor of the bone via the
Runx2/TWIST-RANK/RANKL pathway. Biochem Biophys Res Commun.
2018;505(4):1003-9. |
|